Form 4: BridgeBio Director Exercises Options, Sells Shares

BridgeBio Pharma Director Randal W. Scott exercised stock options and subsequently sold a portion of his shares under a Rule 10b5-1 plan.

Summary

• Randal W. Scott, a Director of BridgeBio Pharma, Inc. (BBIO), reported transactions on November 17, 2025.
• Scott exercised options to acquire 10,000 shares of Common Stock at an exercise price of $16.75 per share.
• Following the option exercise, Scott sold 3,801 shares of Common Stock at a weighted average price of $66.2481 per share, with prices ranging from $65.64 to $66.63.
• Additionally, Scott sold another 6,199 shares of Common Stock at a weighted average price of $66.8908 per share, with prices ranging from $66.65 to $67.48.
• All reported transactions were conducted pursuant to a Rule 10b5-1 sales plan adopted by Scott on June 27, 2025.
• After these transactions, Scott directly beneficially owns 11,589 shares of Common Stock.
• Scott also indirectly beneficially owns 4,000 shares of Common Stock through Thinking Bench Capital LLC.
• Scott holds 41,501 derivative securities (stock options) with an exercise price of $16.75, expiring on June 21, 2033.
• The stock options vested one-third on June 21, 2024, and will continue to vest one-third annually, with full vesting by June 21, 2026, contingent on continued board service.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the insider selling of shares, even though it was pre-planned. While the director realized a significant profit from option exercise, the reduction in direct holdings could be interpreted as a lack of increasing confidence in the company's near-term stock appreciation, despite the 10b5-1 plan.

Positives

• The exercise of stock options at $16.75 and subsequent sale at prices around $66-$67 indicates a significant profit for the director, reflecting past stock appreciation.
• The transactions were executed under a pre-arranged Rule 10b5-1 plan, which suggests the sales were not based on new, non-public information.

Negatives

• The net effect of the transactions is a reduction in the director's direct beneficial ownership of common stock, which can sometimes be perceived negatively by investors as insider selling.

Future Outlook

na

Industry Context

Insider transactions, such as option exercises and subsequent share sales, are common in the biotechnology and pharmaceutical industries, particularly for long-serving directors or executives. These transactions often reflect a director's personal financial planning and diversification strategies, especially when executed under a Rule 10b5-1 plan, which provides an affirmative defense against insider trading allegations.

Corporate Governance

Related Party Transactions

• Randal W. Scott indirectly beneficially owns 4,000 shares of Common Stock through Thinking Bench Capital LLC.

Stakeholder Impact

• Shareholders may observe the director's sale of shares and consider it in their investment decisions, although the pre-planned nature (10b5-1) mitigates concerns about opportunistic selling.

Next Steps

• Remaining stock options will continue to vest annually, with full vesting expected by June 21, 2026, subject to Randal W. Scott's continued service on the board of directors.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Randal W. Scott, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Director Transactions